Unbalanced risk-benefit analysis of ADHD drugs
نویسندگان
چکیده
منابع مشابه
ADHD drugs and cardiovascular risk.
1445 box” warning describing the cardiovascular risks of stimulant drugs used to treat attention deficit–hyperactivity disorder (ADHD). This action was unexpected, largely because the FDA had not requested a review of current labeling for this class of drugs; it had merely asked for recommendations of approaches to studying the cardiovascular risks associated with these drugs. The committee, ho...
متن کاملMulti-Criteria Risk-Benefit Analysis of Health Care Management
Abstract Purpose of this paper: The objectives of this paper are two folds: (1) utilizing hierarchical fuzzy technique for order preference by similarity to ideal solution (TOPSIS) approach to evaluate the most suitable RFID-based systems decision, and (2) to highlight key risks and benefits of radio frequency identification technology in healthcare industry. Design/methodology/approach: R...
متن کاملAssessing the Benefit-Risk for New Drugs
The U.S. Food and Drug Administration (FDA) regulates which drugs can bemarketed in the U.S. as well as their label requirements. A congressionally authorized advisory committee process allows the FDA to receive input from outside experts on important regulatory decisions (1). Further, the advisory committee process enhances transparency by allowing the public, including health care professiona...
متن کاملFurthering benefit/risk ratio and cost effectiveness of anticancer drugs.
BACKGROUND In Russia, the incidence of melanoma is increasing steadily. The approved standard of specialized medical care for melanoma of the skin defined the range of drugs, recommended for the provision of quality health care. However, it appears that the most effective innovative and safe medicines are at the same time the most expensive drugs. The most important is the assessment of drug us...
متن کاملRisk-Benefit Profile of Novel Anti-diabetic Drugs: Current Perspectives
We are facing a paradigm shift in the era of antidiabetics, because agents marketed after 2008 (i.e., after the rosiglitazone saga) are not only required to reduce levels of HbA1, but also to demonstrate beneficial or at least neutral effect with regard to cardiovascular (CV) outcomes (Figure 1). This is of paramount relevance, considering that the risk of developing CV disease is two-fold high...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Psychiatry
سال: 2018
ISSN: 2215-0366
DOI: 10.1016/s2215-0366(18)30349-3